15.6K(top 2%)
articles
435.7K(top 2%)
citations
2,978(top 3%)
★★ articles
93(top 3%)
★★★ articles
2.3(top 25%)
Avg IF
226(top 2%)
H-Index
374(top 2%)
G-Index
2,696
journals

Most Cited Articles of Bayer in 2016

TitleJournalYearCitations
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis and Rheumatology20161.3K
The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013Lancet, The2016791
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis Care and Research2016717
PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved DrugsJournal of Pharmaceutical Sciences2016416
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trialJournal of Hepatology2016407
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillationEuropean Heart Journal2016319
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON studyJournal of Hepatology2016189
Ethylene vinyl acetate (EVA) as a new drug carrier for 3D printed medical drug delivery devicesEuropean Journal of Pharmaceutical Sciences2016173
A comprehensive insight on ocular pharmacokineticsDrug Delivery and Translational Research2016167
Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AFEuropean Heart Journal2016167
Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testingALTEX: Alternatives To Animal Experimentation2016161
Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older AdultsJAMA Neurology2016157
Three-Dimensional Printed PCL-Based Implantable Prototypes of Medical Devices for Controlled Drug DeliveryJournal of Pharmaceutical Sciences2016147
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomasAnnals of Oncology2016140
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy useBlood2016122
Mechanism of inhibition of human glucose transporter GLUT1 is conserved between cytochalasin B and phenylalanine amidesProceedings of the National Academy of Sciences of the United States of America2016112
Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876ChemMedChem2016108
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial FibrillationCirculation2016102
Structural analysis of human KDM5B guides histone demethylase inhibitor developmentNature Chemical Biology2016102
Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trialLancet Respiratory Medicine,the201698
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AFJournal of the American Heart Association201694
On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AFCirculation201693
Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global RegistryInternational Journal of Stroke201686
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisArthritis and Rheumatology201669
Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trialLancet Respiratory Medicine,the201669